Home Immunity Covid-19 antibodies found in non-immune blood cancer patients after receiving booster shot

Covid-19 antibodies found in non-immune blood cancer patients after receiving booster shot

0

Patients with blood cancers have been reported to be less likely to develop immunity to COVID-19 vaccination. However, new data has been found indicating that those who were previously vaccinated with no immunity, then followed up with a booster dose, eventually developed antibodies against the virus.

Patients with blood cancers have been reported to be less likely to develop immunity to COVID-19 vaccination. However, new data has been found indicating that those who were previously vaccinated with no immunity, then followed up with a booster dose, eventually developed antibodies against the virus.

These data are based on a study published in July in the journal of the American Cancer Society, Cancer.

The study authors retrospectively analyzed the serological responses to initial and booster COVID-19 vaccination in 378 patients with hematological malignancies or blood cancers such as leukemia, lymphoma and multiple myeloma, and reported then tracked results related to COVID-19.

Antibodies were found in 181 patients after initial vaccination; patients who had an active malignancy or those who were recently treated with a B-cell depleting monoclonal antibody had the lowest levels of antibodies developed, according to the study.

For initial non-responders to vaccination, immunity after a booster dose occurred in 48 of 85 patients (56%). The rate of seroconversion or immunity after the booster was similar for patients on (53%) and off (58%) active treatment.

The study results also revealed that 33 patients (8.8%) developed COVID-19 infection and three succumbed to COVID-19-related deaths (0.8%).

The researchers found that the post-vaccination antibody response may not be associated with a decrease in any COVID-19 infection. They suggested effective vaccination with booster, supplemented by passive immunization with tixagevimab/cilgavimab in the absence of seroconversion, effective in the otherwise high-risk population.